Groups Issue Joint Statement Advocating for Patient Rights in ACA Fight
Seventeen patient advocacy groups have jointly released a statement on behalf of patients with preexisting conditions who utilize services provided by the ACA.
All articles by Lauren Biscaldi
FDA: New Plan for Regulations, Oversight of Dietary Supplement Industry
The Food and Drug Administration has announced a new plan to significantly modernize the regulation and oversight of dietary supplements.
Ivy League Rule Change Linked to Fewer Concussions During NCAA Football Games
A 2016 experimental rule change in National Collegiate Athletic Association (NCAA) Division I Ivy League play has been linked to a reduction in concussions among players.
Variations in Influenza Vaccination Coverage Among Healthcare Employees Reported
Wide variations in influenza vaccine coverage have been noted across healthcare personnel based on occupation and worksite.
Adolescents With Chronic Headache May Benefit From Targeted Group Education
Focused group education and lifestyle management for chronic headaches may be an effective, low-cost treatment mechanism.
Examining the Relationship Between Vitamin D and Progressive Multiple Sclerosis
Vitamin D deficiency is a risk factor for multiple sclerosis.
Screening for Comorbid Psychiatric Conditions in MS: Use of Validated Screening Tools
Barriers to using screening tools included lack of time and lack of insurance compensation.
Safety, Efficacy of Novel Oral Therapy for Relapsing MS
Ozanimod decreased both T2 and T1 brain lesions and brain volume loss in patients with relapsing multiple sclerosis.
Exploring New Treatments for MS: Safety, Efficacy of Intravenous Cladribine
Researchers examined patients’ disease course and the number of clinical attacks to determine the safety and efficacy of intravenous cladribine.
CRISP Trial Update: Suitability of Antipsychotic Medications for MS
CRISP will determine the suitability of clozapine and risperidone as a treatment for progressive multiple sclerosis.
-
Loading...
-
Loading...
Next post in ACTRIMS 2018
